Low microsatellite instability: A distinct instability type in gastric cancer?

"Declarations Conflict of interestWW has attended advisory boards and served as a speaker for Roche, MSD, BMS, AstraZeneca, Pfizer, Merck, Lilly, Boehringer, Novartis, Takeda, Bayer, Amgen, Astellas, Eisai, Johnson & Johnson, Janssen, Illumina, Siemens, Agilent, ADC, GSK, and Molecular Health. WW received research funding from Roche, MSD, BMS, and AstraZeneca. NP has attended advisory boards of Novartis, Bayer, Lilly, Roche, AstraZeneca. NP received speaker fees from Illumina, Thermo Fisher Scientific, Roche, BMS, AstraZeneca, Bayer, MSD, QuiP and received travelling support from BMS, Illumina, Thermo Fisher Scientific, PGDx. The other authors declare no conflicts of interest. Conflict of interest WW has attended advisory boards and served as a speaker for Roche, MSD, BMS, AstraZeneca, Pfizer, Merck, Lilly, Boehringer, Novartis, Takeda, Bayer, Amgen, Astellas, Eisai, Johnson & Johnson, Janssen, Illumina, Siemens, Agilent, ADC, GSK, and Molecular Health. WW received research funding from Roche, MSD, BMS, and AstraZeneca. NP has attended advisory boards of Novartis, Bayer, Lilly, Roche, AstraZeneca. NP received speaker fees from Illumina, Thermo Fisher Scientific, Roche, BMS, AstraZeneca, Bayer, MSD, QuiP and received travelling support from BMS, Illumina, Thermo Fisher Scientific, PGDx. The other authors declare no conflicts of interest."

"Funding Open Access funding enabled and organized by Projekt DEAL. This work was supported by the Wilhelm Sander Foundation, grant no. 2019.156.1 to GK."